Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance

Oruka Therapeutics Inc. Common StockTrade
Super Group (SGHC) Limited Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Oruka Therapeutics Inc. Common Stock vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.69B). The key difference: Oruka Therapeutics Inc. Common Stock and Super Group (SGHC) Limited Ordinary Shares are close in size by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.79% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Super Group (SGHC) Limited Ordinary Shares for 6 Days on average.

ORKASGHC
Market Cap
$5.18B$5.69B
Volume
490,7982,162,759
Sector
HealthConsumer Cyclical
52-Week High
$113.08$15.59
52-Week Low
$26.19$8.52
Typical Hold Time
0 Days6 Days
Enterprise Value
$4.31B$5.23B
Dividend Yield
—1.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Super Group (SGHC) Limited Ordinary Shares

SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.

SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ORKA
100% Buy0% Sell
Avg holding period · 0 Days
SGHC

No sentiment data available yet.

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →

About Super Group (SGHC) Limited Ordinary Shares

Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.

Read more on SGHC →